EmpresasβΊABOS
ABOS Β· Acumen Pharmaceuticals, Inc.
productos biologicos Β· CIK 0001576885
Acumen Pharmaceuticals, Inc. (ABOS) cotiza en el NASDAQ y se dedica a productos biologicos. Aqui estan 3 documentos que ha presentado ante la SEC, desde 12 ago 2026. En sus informes aparecen frases que este sitio vigila: duda sustancial sobre la continuidad de la empresa y designacion de via rapida (fast track). Estan citadas literalmente mas abajo.
- Documentos
- 3
- Ultimo
- 12 ago 2026
recogidos hasta hoy
Registro de acciones para empleados
Todavia no se publican los trimestres de caja ni la dilucion de esta empresa: hacen falta datos de sus informes que solo se recogen de las que se siguen de cerca. Lo que ves abajo son sus documentos tal y como los presento ante la SEC.
Documentos presentados ante la SEC
2026
- S-8Registro de acciones para empleadosEDGAR
- 10-QInforme trimestralEDGAR
Duda sustancial sobre la continuidad de la empresaver la frase en el documento (ingles)
β¦Accounting Standards Codification (βASCβ) 205-40, Presentation of Financial Statements-Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Companyβs ability to continue as a going concern. The Company has incurred operating losses since inception. As of June 30, 2026, the Company had an accumulated deficit of $499.9 million and had cash and cash equivalents and marketable securities ofβ¦
- 8-KHecho relevanteEDGAR
Designacion de via rapida (Fast Track)ver la frase en el documento (ingles)
β¦soluble AΞ²Os, sabirnetug aims to address the hypothesis that soluble AΞ²Os are an early and persistent underlying cause of the neurodegenerative process in Alzheimerβs disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD. About ALTITUDE-AD (Phase 2) Initiated in 2024, ALTITUDEβ¦